EU/3/20/2318: Orphan designation for the treatment of amyotrophic lateral sclerosis

Dextran sulfate low molecular weight


On 21 August 2020, orphan designation EU/3/20/2318 was granted by the European Commission to TikoMed AB, Sweden, for dextran sulfate low molecular weight (also known as ILB) for the treatment of amyotrophic lateral sclerosis.

Key facts

Active substance
Dextran sulfate low molecular weight
Intended use
Treatment of amyotrophic lateral sclerosis
Orphan designation status
EU designation number
Date of designation

TikoMed AB
Karlsfältsvägen 349
SE-26365 Viken
Telephone: + 46 42 23 84 40

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating